VX809

Lumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.


Cat. No.: EX-A178	Purity: >99% by HPLC

	Chemical structure of VX809

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
1g	685	In-stock
5g	2055	In-stock
10g	3055	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	936727-05-8
Purity	>99% by HPLC
Formula	C24H18F2N2O5
Mol Weight	452.4069
State	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Van Goor F, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A, 2011, 108(46), 18843-18848.
CoA	CoA of VX809

Smiles:	CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O


		Search